Original language | English |
---|---|
Article number | 88 |
Journal | Blood cancer journal |
Volume | 8 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2018 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood cancer journal, Vol. 8, No. 9, 88, 01.09.2018.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
AU - Ottmann, Oliver
AU - Saglio, Giuseppe
AU - Apperley, Jane F.
AU - Arthur, Christopher
AU - Bullorsky, Eduardo
AU - Charbonnier, Aude
AU - Dipersio, John F.
AU - Kantarjian, Hagop
AU - Khoury, Hanna Jean
AU - Kim, Dong Wook
AU - Healey, Diane
AU - Strauss, Lewis
AU - Cortes, Jorge E.
N1 - Funding Information: O.O. has acted as a consultant, advisor, or speaker for ARIAD, Bristol-Myers Squibb, Celgene, Fusion Pharma, Novartis, Pfizer, Roche, and SUN Pharma. G.S. has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. J.F.A. is an NIHR Senior Investigator and acknowledges the support of the Imperial College NIHR Biomedical Research Centre and has acted as a consultant, speaker, and advisor for ARIAD, Bristol-Myers Squibb, Incyte, Novartis, Pfizer, and SUN Pharma. C.A. has served on advisory boards and acted as a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. E.B. has no disclosures to declare. A.C. has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. J.F.D. has no disclosures to declare. H.K. has served on advisory boards for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. H.J.K. has no disclosures to declare. D.-W.K. has received research funding from and served on an advisory committee for Bristol-Myers Squibb. D.H. and L.S. are employees of Bristol-Myers Squibb. J.C. has served as a consultant to and received research funding from ARIAD, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. Funding Information: The authors would like to thank all participating study sites for this Bristol-Myers Squibb–sponsored analysis. Professional medical writing and editorial assistance were provided by Kelly M. Fahrbach, PhD, of StemScientific, an Ashfield Company, part of UDG Healthcare plc, funded by Bristol-Myers Squibb. The authors did not receive financial compensation from Bristol-Myers Squibb for authoring this manuscript.
PY - 2018/9/1
Y1 - 2018/9/1
UR - http://www.scopus.com/inward/record.url?scp=85052925537&partnerID=8YFLogxK
U2 - 10.1038/s41408-018-0122-3
DO - 10.1038/s41408-018-0122-3
M3 - Letter
C2 - 30190469
AN - SCOPUS:85052925537
SN - 2044-5385
VL - 8
JO - Blood cancer journal
JF - Blood cancer journal
IS - 9
M1 - 88
ER -